|Bid||6.77 x 1800|
|Ask||6.78 x 1300|
|Day's Range||6.66 - 7.04|
|52 Week Range||6.66 - 25.10|
|Beta (3Y Monthly)||4.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cannabis stocks fell for a third straight session on Wednesday, as Tilray’s mixed third-quarter earnings failed to light a fire under the battered sector.
A Canadian regulator told weed companies earlier this week to get better at offering conflict of interest disclosure around mergers and acquisitions.
The Canopy Growth earnings report was weaker than expected for the Canadian cannabis giant. Canopy Growth fell while other marijuana stocks dipped.
For a change, the market was in the red at the start of today's PreMarket Prep Show. Trump comments that he will increase tariffs if a deal isn't reached came Tuesday and the markets backed off intra-day highs. Unfortunately, Cronos Group (NYSE: CRON) was unable to rally off its third-quarter report and the same can be said for Tilray Inc. (NASDAQ: TLRY).
Cronos Group kicked off the September quarter earnings season for the cannabis sector on Tuesday with a report showing a profit driven by a one-time gain and lower-than-expected revenue.
Cronos earnings were positive, but may not be comparable. Sales jumped but missed views, a common problem for the industry.
Tilray earnings are on tap late, after mixed Cronos Group earnings. Tilray and Cronos fell while other marijuana stocks were mixed.
Over the last six months, Cronos Group Inc. (NASDAQ: CRON ) shares have fallen by 43.3%. The Analyst Bank of America Merrill Lynch’s Christopher Carey maintained a Buy rating on Cronos Group with a $13 ...
Cannabis stocks traded lower on Tuesday after third-quarter earnings season in the group got off to a lackluster start. On Monday evening, OrganiGram Holdings Inc (NASDAQ: OGI) preannounced third-quarter revenue that was about 45% below consensus Wall Street estimates. Zuanic said OrganiGram is now anticipating adjusted EBITDA will fall into negative territory in the fiscal fourth quarter after reporting positive EBITDA in recent quarters.
Cronos Group (NASDAQ: CRON) was the first of three issues in the sector to report this week. As a result, the price action was not revealing on how the issue may trade off the open. CBS Corporation (NYSE: CBS) announced a mixed report, coming up shy on sales by $65 million.
All eyes will be on President Trump Tuesday for U.S.-China trade war updates. Walmart, Nvidia, and others are set to report their quarterly earnings. And why Casey's General Stores (CASY) is a Zacks Rank 1 (Strong Buy) right now...
It’s been a brutal year for cannabis investors, with the ETF MANAGERS TR/TIERRA XP LATIN AME (NYSE: MJ ) down another 1.2% this month ahead of a series of major cannabis earnings reports this week. Cronos ...
Marijuana seller Cronos reported a surprise profit based on generally accepted accounting principles, sending its shares abruptly higher, although revenue fell short of expectations.
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) posted third-quarter net revenue of CA$12.7 million ($9.6 million) Tuesday, up by 238% from CA$3.8 million in the same quarter of 2018. Cronos Group disclosed quarterly basic earnings per share of CA$2.33 and diluted earnings per share of CA$0.53 compared to a loss per basic and diluted share of CA$0.04 in the same quarter of last year.
Cronos (CRON) delivered earnings and revenue surprises of 33.33% and -3.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group Inc (NASDAQ: CRON ) shares are moving in premarket trading after reporting profitable earnings that missed Wall Street revenue estimates. It’s the greenest week of earnings: after CRON, a ...
Cronos Group Inc and Tilray Inc both reported selling prices that nearly halved, while expenses for both the Canadian pot producers soared in the third quarter. Prices for weed have taken a hit in Canada as demand has lagged expectations set last year, when the nation became the first among G7 countries to legalise recreational marijuana. The cannabis industry in the country is also facing a supply glut as companies ramp up production to dominate the nascent industry.
A resilient stock market awaits President Trump's speech Tuesday for China trade deal hints. Cronos reports early, with fellow marijuana stock Tilray due late.
Cronos Group Inc. said Tuesday it had a profit of C$788.4 million ($595.2 million), or 53 cents a share, in the third quarter, after a loss of C$7.2 million, or 4 cents a share, in the year-earlier period. The profit was mostly due to a C$835 million gain on the revaluation of derivative liabilities. Revenue came to C$12.7 million, up from $3.8 million a year ago. The FactSet consensus was for a loss of 3 cents and revenue of C$13.7 million. The company sold 3.142 kilograms of cannabis in the Canadian adult-use market in the quarter, up from 514 kg sold in the year-earlier period. Revenue per gram sold fell to C$3.75 from C$6.44. Shares rose 2% in premarket trade, but are down 22% in 2019, while the ETFMG Alternative Harvest ETF has fallen 23% and the S&P 500 has gained 23%.
Prices for weed have taken a hit in Canada as demand has lagged expectations set last year, when the nation became the first among G7 countries to legalize recreational marijuana. The cannabis industry in the country is also facing a supply glut as companies ramp up production to dominate the nascent industry. Cronos' net product revenue per gram sold outside the United States fell to C$3.75 in the third quarter, while Tilray's average net selling price per gram also nearly halved to $3.25.
Nov 12 (Reuters) - Cronos Group Inc reported a bigger quarterly loss on Tuesday, as the Canadian marijuana producer was weighed down by lower margins and surge in expenses.
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced Operational.
Weed companies in Canada have consistently over-promised and under-delivered for investors at earnings time, a big reason previously fattened valuations have been on a severe diet. The next major test for the tortured set of names begins Monday.